One of the mechanisms underlying rapid revascularization is that antiangiogenic treatment triggers tumour hypoxia, which induces expression of hypoxia-regulated angiogenic factors such as VEGF (ref. 41). The gene discussed is VEGFA; the disease is neoplasm.